IL216987A0 - Composition for the treatment of benign prostate hyperplasia - Google Patents

Composition for the treatment of benign prostate hyperplasia

Info

Publication number
IL216987A0
IL216987A0 IL216987A IL21698711A IL216987A0 IL 216987 A0 IL216987 A0 IL 216987A0 IL 216987 A IL216987 A IL 216987A IL 21698711 A IL21698711 A IL 21698711A IL 216987 A0 IL216987 A0 IL 216987A0
Authority
IL
Israel
Prior art keywords
treatment
composition
benign prostate
prostate hyperplasia
hyperplasia
Prior art date
Application number
IL216987A
Other languages
English (en)
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of IL216987A0 publication Critical patent/IL216987A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
IL216987A 2009-07-06 2011-12-15 Composition for the treatment of benign prostate hyperplasia IL216987A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09251738 2009-07-06
US23581609P 2009-08-21 2009-08-21
PCT/IB2010/001785 WO2011004260A2 (en) 2009-07-06 2010-07-05 Composition for the treatment of benign prostate hyperplasia

Publications (1)

Publication Number Publication Date
IL216987A0 true IL216987A0 (en) 2012-02-29

Family

ID=41112615

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216987A IL216987A0 (en) 2009-07-06 2011-12-15 Composition for the treatment of benign prostate hyperplasia

Country Status (18)

Country Link
US (2) US20110039787A1 (enExample)
EP (1) EP2451469B1 (enExample)
JP (1) JP2012532188A (enExample)
KR (1) KR20120038956A (enExample)
CN (1) CN102470159A (enExample)
AR (1) AR081439A1 (enExample)
AU (1) AU2010269958A1 (enExample)
BR (1) BR112012000185A2 (enExample)
CA (1) CA2766008A1 (enExample)
IL (1) IL216987A0 (enExample)
MX (1) MX2012000315A (enExample)
NZ (1) NZ597060A (enExample)
RU (1) RU2011152514A (enExample)
SA (1) SA110310575B1 (enExample)
TW (1) TW201105344A (enExample)
UY (1) UY32769A (enExample)
WO (1) WO2011004260A2 (enExample)
ZA (1) ZA201109513B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
WO2010125468A1 (en) * 2009-05-01 2010-11-04 Ferring International Center Sa Composition for the treatment of prostate cancer
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
WO2013178788A2 (en) 2012-06-01 2013-12-05 Ferring B.V. Manufacture of degarelix
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
US12274680B2 (en) 2022-09-13 2025-04-15 II George William Creasy Treatment of benign prostatic hypertrophy with capsinoids

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JP2719233B2 (ja) * 1991-04-25 1998-02-25 デゲンギ，ロマノ 黄体形成ホルモン放出ホルモン拮抗ペプチド
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
GB0506759D0 (en) * 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
EP2257324B1 (en) * 2008-02-11 2016-07-27 Safety Syringes, Inc. Syringe with safety needle guard and clip to prevent release of guard during reconstitution process
WO2010125468A1 (en) * 2009-05-01 2010-11-04 Ferring International Center Sa Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
PL2632934T3 (pl) * 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
ES2655172T3 (es) * 2011-07-15 2018-02-19 Ferring B.V. Procedimiento para preparación temporal de una colonoscopia en la que se administra una composición de picosulfato

Also Published As

Publication number Publication date
KR20120038956A (ko) 2012-04-24
AR081439A1 (es) 2012-09-05
US20110039787A1 (en) 2011-02-17
AU2010269958A1 (en) 2012-01-19
JP2012532188A (ja) 2012-12-13
TW201105344A (en) 2011-02-16
US20120172302A1 (en) 2012-07-05
SA110310575B1 (ar) 2014-10-23
CN102470159A (zh) 2012-05-23
MX2012000315A (es) 2012-02-13
UY32769A (es) 2011-02-28
CA2766008A1 (en) 2011-01-13
BR112012000185A2 (pt) 2017-06-13
RU2011152514A (ru) 2013-08-20
WO2011004260A2 (en) 2011-01-13
WO2011004260A3 (en) 2011-05-19
ZA201109513B (en) 2012-09-26
NZ597060A (en) 2013-05-31
EP2451469B1 (en) 2014-08-20
EP2451469A2 (en) 2012-05-16

Similar Documents

Publication Publication Date Title
IL216987A0 (en) Composition for the treatment of benign prostate hyperplasia
ZA201107879B (en) Composition for the treatment of prostate cancer
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
IL248204A0 (en) Combined treatment of tumors expressing 38cd
HUE043569T2 (hu) Vegyületek rák kezelésére
IL218987A0 (en) Methods and compositions for treating cancer
IL206970A0 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
EP2461814A4 (en) PROSTATE CANCER TREATMENT
IL251083B (en) Compounds and preparations for the treatment of cancer
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
PL2559439T3 (pl) Preparat farmaceutyczny do leczenia łagodnego rozrostu gruczołu krokowego
IL214349A0 (en) Compositions and methods for the treatment of cancer
SG173672A1 (en) Novel ortho-aminoamides for the treatment of cancer
PL2605764T3 (pl) Kompozycje do leczenia nowotworu
IL238394B (en) Preparations containing a combination of factors for the treatment of cancer
IL219636A0 (en) Methods and compositions for treating solid tumors and other malignancies
PT3330383T (pt) Grn163l para utiliização como inibidor de telomerase no tratamento de cancro
EP2083840A4 (en) IMPROVED TREATMENT FOR BENEFICIAL PROSTATE HYPERPLASIA
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
SG10201700334XA (en) Composition useful for the prevention or reduction of the progression of prostate cancer
GB0917745D0 (en) Compositions for the prevention or treatment of migraine
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0809319D0 (en) The treatment of puritus
GB0817056D0 (en) Polypeptide for treatment of cancer